Trauma Doesn't Stay in the Mind: What PTSD May Do to the Body
Evidence review & editorial synthesis
A traumatic event happens in the outside world. PTSD is diagnosed through what happens afterward in the mind: intrusive memories, hypervigilance, avoidance, altered mood and persistent threat.
But the disorder may not stop there.
A growing body of research suggests that PTSD can be accompanied by measurable changes in immune signaling, stress hormones, cardiovascular physiology and even molecular markers associated with biological aging.
A new study now adds another layer. Researchers examined blood from 34 people with PTSD and 32 healthy controls and asked an unusual question: are the immune cells themselves using energy differently?
The answer was yes.
Immune cells appeared to be running in a different metabolic state
The researchers examined several types of peripheral immune cells, including CD4 and CD8 T cells, B cells, natural killer cells and monocytes.
Across multiple cell populations, PTSD was associated with higher levels of markers involved in glycolysis and the oxidative pentose phosphate pathway. Those pathways help cells rapidly process glucose and generate the molecular resources needed for activation, antioxidant defense and biosynthesis.
The differences were not enormous, but they were consistent enough to appear across several immune-cell types, with effect sizes generally in the moderate range.
People with PTSD also had higher circulating IL-6, an inflammatory signaling molecule that has repeatedly appeared in trauma and stress research.
That creates an intriguing possibility. The immune system in PTSD may not simply be producing more inflammatory signals. Some immune cells may be operating in a different metabolic mode.
Researchers call this immunometabolism: the idea that what an immune cell does is tightly connected to how it produces and uses energy.
An activated immune cell does not run metabolically like a resting one. It can increase glucose uptake, shift toward glycolysis and redirect metabolic pathways to support proliferation, signaling and production of inflammatory molecules.
The new results raise the possibility that persistent psychological stress is associated with some version of that metabolic shift.
This is not the first evidence that PTSD reaches beyond the brain
The study is small and cross-sectional, so it cannot prove that PTSD caused the cellular changes.
But it fits a much larger literature.
Meta-analyses of PTSD have repeatedly reported higher levels of inflammatory markers including C-reactive protein, IL-6 and TNF-alpha. The size and consistency of those differences vary, and inflammation is influenced by many factors including sleep, body weight, smoking, medication and physical activity.
Still, the signal has appeared often enough that PTSD is increasingly studied as a disorder with systemic as well as psychological features.
The stress system provides one plausible bridge.
Trauma-related disorders can alter signaling through the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis, which regulates cortisol and the body's response to stress. Both systems communicate directly with immune organs and immune cells.
A brain that repeatedly predicts danger can therefore influence heart rate, vascular tone, hormone release and immune activity even when the original traumatic event is long over.
That does not make PTSD 'all in the body' any more than it is 'all in the mind.' It suggests that the distinction itself may be misleading.
The physical consequences may be clinically important
The most important question is not whether a blood marker changes. It is whether PTSD is associated with actual disease.
Here the evidence is considerably stronger.
A 2024 systematic review and meta-analysis including more than 335,000 participants found that PTSD was associated with about a 42% higher risk of cardiovascular disease overall and a similar increase in myocardial infarction risk. The pooled estimate for stroke was roughly doubled, although those studies were more heterogeneous and therefore less certain.
Those numbers do not establish that immune activation is the cause.
People with PTSD can also experience severe sleep disruption, reduced activity, smoking, alcohol use, metabolic changes, medication effects and chronic autonomic arousal. All of those can contribute to cardiovascular risk.
But inflammation and altered immune metabolism provide plausible biological pathways connecting persistent threat physiology with longer-term disease.
The new study is therefore interesting not because immune cells offer a new diagnostic test, but because it begins to fill in a mechanistic gap between psychological trauma and physical health.
Trauma may also leave epigenetic traces
Another rapidly developing field examines epigenetics.
Epigenetic marks do not change the letters of DNA. Instead, chemical modifications such as DNA methylation can influence how readily genes are used.
PTSD research has repeatedly implicated genes involved in the stress response and immune regulation, including components of the glucocorticoid system such as FKBP5 and NR3C1.
One particularly provocative question is whether PTSD is associated with faster biological aging.
In 2025, researchers combined longitudinal data from seven military and civilian cohorts totaling 1,367 people. Participants who developed PTSD or whose symptoms worsened showed greater acceleration over time on the Horvath DNA-methylation aging measure than would have been expected from their baseline values.
But another widely used epigenetic clock, GrimAge, did not show the same association.
That inconsistency matters. Epigenetic clocks are biomarkers, not literal speedometers for the aging of every organ. The result is intriguing evidence that PTSD may influence some molecular aging processes, not proof that trauma universally accelerates aging.
Can the biological imprint be reversed?
This may be the most consequential question.
If persistent trauma can alter stress regulation, immune signaling and epigenetic patterns, successful treatment might theoretically change some of those systems again.
There are early hints that this can happen.
Small studies of psychotherapy have reported changes in DNA methylation at genes related to stress and neural function alongside symptom improvement. Reviews have highlighted markers involving BDNF, HTR3A and stress-response pathways as possible candidates.
But the evidence remains preliminary. We do not yet have large randomized trials showing that treating PTSD reliably normalizes inflammation, immune-cell metabolism or biological-age measures and that these changes subsequently reduce heart disease or other physical outcomes.
That is the study researchers now need.
An ideal trial would measure PTSD symptoms, immune-cell metabolism, inflammatory markers, autonomic function and epigenetic signatures before treatment and repeatedly afterward. If psychological recovery were followed by consistent biological normalization, the argument for reversibility would become much stronger.
A psychological disorder with biological consequences
There is a risk in discussing the biology of PTSD badly.
One mistake is to suggest that biological findings are required to prove that psychological suffering is real.
They are not.
The opposite mistake is to assume that because the trigger was psychological, the consequences must remain confined to thoughts and emotions.
The accumulating evidence argues against that division.
The brain regulates hormones, autonomic activity, sleep, metabolism and immune function continuously. Persistent threat processing can therefore propagate through the body through ordinary biological pathways.
The latest study provides a particularly interesting snapshot of that process: immune cells from people with PTSD appeared metabolically different, as though parts of the immune system had adapted to a different physiological environment.
Whether those changes help drive illness, reflect it, or both is still unresolved.
But the broader lesson is increasingly difficult to dismiss.
Trauma can end in minutes. The body's response to it may continue for years.
Scientific References & Further Reading
- Anchor Study: “Immunometabolic alterations in post-traumatic stress disorder.” (Brasanac J, El-Ahmad L, Mollerup E, et al. Immunometabolic alterations in post-traumatic stress disorder. Brain, Behavior, and Immunity. 2026. doi:10.1016/j.bbi.2026.107031.)
- Inflammation: “Aberrations in peripheral blood interleukin-6 levels in post-traumatic stress disorder: A systematic review and meta-analysis.” (Aberrations in peripheral blood interleukin-6 levels in post-traumatic stress disorder: A systematic review and meta-analysis. Behavioural Brain Research. 2026;497:115881. doi:10.1016/j.bbr.2025.115881.)
- Cardiovascular Risk: “Cardiovascular impact of post-traumatic stress disorder: A systematic review and meta-analysis.” (Padhi BK, Khatib MN, Serhan HA, et al. Cardiovascular impact of post-traumatic stress disorder: A systematic review and meta-analysis. Current Problems in Cardiology. 2024;49(8):102632. doi:10.1016/j.cpcardiol.2024.102632.)
- Epigenetic Aging: “PTSD and epigenetic aging: a longitudinal meta-analysis.” (Zhao X, Katrinli S, McCormick BM, et al. PTSD and epigenetic aging: a longitudinal meta-analysis. Psychological Medicine. 2025;55:e142. doi:10.1017/S0033291725000558.)
- Epigenetics and Stress Biology: “Gene expression and epigenetic changes in post-traumatic stress disorder, depression, and anxiety in first responders: A systematic review.” (Alahmad R, Hinchey LM, Shaikh M, Amirsadri A, Javanbakht A. Gene expression and epigenetic changes in post-traumatic stress disorder, depression, and anxiety in first responders: A systematic review. Journal of Psychiatric Research. 2025;182:438-451. doi:10.1016/j.jpsychires.2025.01.032.)
- Treatment and Reversibility: “Trauma, Epigenetic Alterations, and Psychotherapy.” (Nohesara S, Alfonso CA. Trauma, Epigenetic Alterations, and Psychotherapy. Psychodynamic Psychiatry. 2025;53(2):143-150. doi:10.1521/pdps.2025.53.2.143.)
Disclaimer: This article is for informational purposes only and does not provide medical advice. Biomarkers discussed here are research findings and are not established diagnostic tests or treatment targets for PTSD.

